QGEN

Qiagen N.V.

Next est. report 2026-11-03 · AMC

Genomics '25: Genomics Tools & AutomationMedTech Long '26: Diagnostics & Early DetectionRegulatory Testing '26: Food Safety & Testing

Loading…

Loading chart…

Overview

Qiagen N.V. provides "sample to insight" solutions for molecular diagnostics and life sciences. The company offers a broad portfolio including sample preparatio

Qiagen N.V. provides "sample to insight" solutions for molecular diagnostics and life sciences. The company offers a broad portfolio including sample preparation technologies, QuantiFERON for TB testing, QIAstat-Dx for syndromic testing, QIAcuity digital PCR, and Qiagen Digital Insights (bioinformatics). They serve research, biopharma, and clinical labs globally.

Search Keywords Brand Product

QIAsymphony Connect
QIAsprint Connect
QIAmini
Parse Biosciences
QIAcuity
QuantiFERON
QIAstat-Dx
Qiagen Digital Insights
Evercode
Franklin platform
BCID panels
complicated UTI panel
sample preparation automation
single-cell analysis
digital PCR
latent tuberculosis testing
bloodstream infection testing
genomic data interpretation
AI in drug discovery
molecular diagnostics
life sciences tools

Search Keywords Event Phrases

Qiagen Q2 2026 earnings
Qiagen strategic review
Qiagen CEO transition

Search Keywords Policy Regulatory

FDA approval diagnostics
CE Mark diagnostics

What They Do (Plain English & Analogies): Qiagen is like a specialized toolkit provider for scientists and doctors. Imagine you're a detective trying to solve a mystery using tiny clues, like a single hair or a drop of blood. Qiagen provides all the specialized tools and instructions you need to find and analyze those tiny clues (like DNA or RNA) from a sample, understand what they mean, and then use that information to solve the mystery, whether it's diagnosing a disease, discovering a new drug, or identifying a criminal. They help turn raw biological samples into meaningful insights.
Very Brief History: Founded in 1984 and headquartered in Venlo, the Netherlands, Qiagen N.V. has evolved into a global provider of sample to insight solutions for molecular diagnostics and life sciences. The company has expanded its portfolio through both organic development and strategic acquisitions, including STAT-Dx in 2018 for its QIAstat-Dx platform, and more recently, Parse Biosciences in late 2025 for single-cell research and Genoox in mid-2025 for AI-powered genomic software.
"Street Stereotype": Qiagen is generally perceived as a vital, high-margin provider of essential tools and consumables for advanced molecular and early-detection laboratories globally. It's seen as a company deeply embedded in the genomics and diagnostics workflow, offering critical sample preparation kits, assay reagents, and digital PCR instruments.
Subsidiaries On Linked In*: Parse Biosciences — Acquired November 2025; LinkedIn: parse-biosciences
Genoox — Acquired May 2025; LinkedIn: genoox
Customer Sectors & Example Clients: Qiagen's customers are primarily in the molecular diagnostics and life sciences sectors. * **Sectors:** Research (academia, biopharma), clinical diagnostics, forensics, pharmaceutical companies. * **Example Clients:** * Pharma companies (mentioned in relation to QIAsprint Connect). * Testing labs in the U.S. (e.g., DaVita for QuantiFERON testing in dialysis patients). * NASA (for Parse single-cell analysis in space research).
New Customers / Segments They'Re Targeting: Qiagen is actively targeting several new customer segments and applications: * **Single-cell analysis:** Expanding its offering with Parse Biosciences, targeting researchers in this rapidly growing field, including those in space research (NASA collaboration). * **Bloodstream infection testing:** Launching new BCID panels for QIAstat-Dx in Europe and planning FDA approval for the U.S., expanding into critical care diagnostics. * **Latent Tuberculosis (TB) testing:** Expanding QuantiFERON applications beyond immigration testing to include diabetes and dialysis patients (e.g., with DaVita in the U.S.), and developing an AI-enabled tool for assessing progression risk. * **Digital PCR applications:** Expanding QIAcuity portfolio with new gene expression assays and high multiplex kits, and broadening workflow automation through collaboration with Hamilton for cell and gene therapy. * **AI-driven drug discovery:** Collaborating with NVIDIA to combine curated biomedical knowledge with accelerated computing and graph-based AI to help researchers accelerate drug discovery. * **Complicated UTI panels:** Developing a panel for complicated urinary tract infections, targeting a significant unmet clinical need in Europe first, then the U.S.
Supply Chain And Sourcing Geographies: The provided transcript does not contain specific details on Qiagen's supply chain or sourcing geographies. Therefore, this information cannot be credibly provided from the given context.
Sales Geographies And Expansion Plans: Qiagen currently sells its products globally, with reported performance in Q2 2026 across: * **Americas:** Rose 1% CER, led by 2% growth in North America. Sales declined in Brazil and Mexico. * **EMEA (Europe, Middle East, and Africa):** Declined 2% CER. Spain, Belgium, and Poland were up, while Germany, France, and Italy were down. * **Asia Pacific:** Declined 2% CER. Excluding China, the region grew at a low single-digit rate, supported by high teens growth in Japan. China was down in the low teens but showed sequential double-digit percentage improvement. **Expansion Plans:** * Bringing QIAstat-Dx BCID panels for bloodstream infection testing to the U.S. after European launch, with FDA approval expected by year-end 2026. * Launching a complicated UTI panel for QIAstat-Dx in Europe first in the second half of 2027, with plans to move to the U.S. thereafter.
How Key Themes May Help/Hurt: The 'MedTech Long '26: Diagnostics & Early Detection' theme is highly beneficial for Qiagen. * **Help:** Qiagen provides the "vital, high-margin sample preparation kits, assay reagents, and digital PCR tools used universally by advanced molecular and early-detection laboratories globally." As the diagnostics and early detection market grows due to accelerating technological advancements (genomics, AI, multiomics), increasing prevalence of chronic diseases (especially cancer), and supportive regulatory developments (like the MCED Act), the demand for Qiagen's foundational products and bioinformatics solutions will increase. Its digital PCR (QIAcuity) and bioinformatics (QDI) offerings are directly aligned with the theme's drivers of AI and genomic advancements. The expansion of QIAstat-Dx into bloodstream infections and complicated UTIs also aligns with the growing demand for advanced diagnostic solutions. * **Hurt:** While generally positive, the theme's challenges such as "persistent reimbursement pressures and evolving payer policies" and "intensifying competition" could indirectly impact Qiagen if its customers face reduced profitability or market uptake for novel tests, potentially affecting their purchasing power for Qiagen's tools and consumables. However, Qiagen's position as a foundational provider of essential tools mitigates some of this direct impact.

3 Main Long-Term Bull Details

Strong Growth Pillars and Innovation: Qiagen's core growth pillars (Sample Technologies, QIAcuity digital PCR, Qiagen Digital Insights, QuantiFERON) consistently deliver above-market growth, driven by continuous innovation and new product launches like QIAsymphony Connect, QIAsprint Connect, QIAmini, new QIAstat-Dx panels (BCID, complicated UTI), and expanded QIAcuity assays. The acquisition of Parse Biosciences further strengthens its position in the high-growth single-cell analysis market.
Strategic Focus on Automation and Digitalization: The company's strategy to transition customers from manual to automated sample preparation, coupled with its strong bioinformatics offerings (QDI) and collaborations in AI (NVIDIA), positions it well to capitalize on the increasing demand for efficient, scalable, and data-driven solutions in life sciences and diagnostics.
High Profitability and Cash Generation: Qiagen maintains a high level of profitability and generates strong cash flow, providing financial flexibility for continued investment in innovation, targeted acquisitions, and capital returns to shareholders (e.g., increased dividend, share repurchases). This financial strength supports sustained long-term growth.

3 Main Long-Term Bear Details

Exposure to Funding Fluctuations and Market Headwinds: Despite sequential improvements, funding for research and academia, particularly from sources like NIH, remains below prior year levels, which can impact capital sales and the ability of labs to invest in new instruments. Geopolitical factors or economic downturns could further exacerbate these funding pressures.
Competitive Pressures and Market Share Erosion: While Qiagen differentiates its products, it faces intensifying competition across its segments, including from traditional methods (e.g., skin tests for TB) and new entrants in growing markets like latent TB testing. Maintaining market share and pricing power against competitors like Revvity and others will be an ongoing challenge.
Product-Specific Headwinds and Challenging Comparables: Certain product lines, like QuantiFERON, have faced significant headwinds (e.g., reduced U.S. immigration testing demand) and challenging prior-year comparisons, requiring the company to compensate with growth in other areas. While new panels are being introduced for QIAstat-Dx, the business remains sensitive to respiratory testing seasonality and prior-year strength.

Competitors And Differentiation: Qiagen operates in competitive markets with various players: * **Competitors:** Traditional skin tests (TST) and Revvity in latent TB testing, as well as new market entrants. Other syndromic testing providers for QIAstat-Dx. 10x Genomics in single-cell analysis (Parse Biosciences is seen as a cost-effective alternative). * **Differentiation:** * **Sample Technologies:** Driving automation with new systems like QIAsymphony Connect, QIAsprint Connect, and the upcoming QIAmini to transition labs from manual to automated sample preparation. * **Parse Biosciences (Single-cell analysis):** Offers a highly differentiated, instrument-free solution with ease of use, scalability for large volumes (GigaLab), and broad cell coverage. * **QuantiFERON:** Developing a fully automated Sample to Insight workflow with partners DiaSorin and Inpeco, and an AI-enabled tool for assessing TB progression risk. * **QIAstat-Dx:** Expanding its menu into critical areas like bloodstream infections (BCID panels) and complicated UTIs, providing broad pathogen and antimicrobial resistance marker coverage with rapid results. The complicated UTI panel is highlighted as a unique offering. * **QIAcuity (Digital PCR):** Expanding its portfolio with scalable, automated workflows, new gene expression assays, high multiplex kits, and broader workflow automation through collaboration with Hamilton. * **Qiagen Digital Insights (QDI):** Leverages over 25 years of curated biomedical knowledge combined with AI to provide meaningful insights from complex biological data, exemplified by its collaboration with NVIDIA for drug discovery.
Recent Performance & What The Market'S Focused On: Qiagen delivered Q2 2026 results above its outlook for both sales ($535 million, unchanged CER) and adjusted diluted EPS ($0.62 CER), demonstrating business resilience. Growth pillars (Sample Technologies, QIAcuity, QDI) performed well, and QuantiFERON returned to growth despite reduced immigration testing demand. The company reaffirmed its full-year 2026 outlook for 1-2% CER sales growth and at least $2.43 adjusted diluted EPS, expecting stronger growth in the second half driven by the cessation of NeuMoDx and DIALUNOX headwinds, new product launches (Sample Tech systems, QIAstat panels, QIAcuity offerings), and contributions from Parse. The market is focused on: * **Acceleration of growth in H2 2026:** Particularly the expected sequential improvement from -1% in H1 to 3-4% in H2, driven by new product launches and easier comparisons. * **Performance of key growth pillars:** Especially Sample Technologies, QIAcuity, and the recovery of QuantiFERON towards its $500 million target. * **Strategic review and CEO transition:** The ongoing process of assessing options to increase shareholder value and the transition to a new CEO in H2 2026. * **Capital deployment:** Questions around share buybacks and the company's approach to returning capital to shareholders while investing in innovation. * **Uptake of new products:** Such as QIAsymphony Connect, QIAsprint Connect, QIAmini, QIAstat-Dx BCID and complicated UTI panels, and expanded QIAcuity offerings.

Revenue Segments And Estimated Mix: Sample Technologies — Mix: Largest segment, 9% CER growth in Q2 2026; Source: Q2 2026 transcript; Trend: Expected to move double digit in H2 2026
Diagnostic Solutions (QuantiFERON) — Mix: Significant segment, 1% CER growth in Q2 2026; Source: Q2 2026 transcript; Trend: Returned to growth in Q2, targeting $500M for FY26 despite reduced immigration testing
Diagnostic Solutions (QIAstat-Dx) — Mix: Significant segment, -7% CER decline in Q2 2026; Source: Q2 2026 transcript; Trend: Impacted by challenging prior year respiratory comparison, strong growth in GI and meningitis panels. Expected high single to low double-digit growth in H2 2026.
Diagnostic Solutions (PCR and Nucleic Acid Amplification - QIAcuity) — Mix: Growing segment, -8% CER decline in Q2 2026 overall, QIAcuity double-digit growth; Source: Q2 2026 transcript; Trend: QIAcuity delivered double-digit growth driven by consumables, offset by weaker OEM demand. QIAcuity expected to accelerate in H2 2026.
Genomics and NGS (Qiagen Digital Insights) — Mix: Growing segment, solid single-digit growth in Q2 2026; Source: Q2 2026 transcript
Genomics and NGS (Consumables for universal NGS panels) — Mix: Growing segment, >20% CER growth in Q2 2026; Source: Q2 2026 transcript
Genomics and NGS (Other genomics products) — Mix: Moderated overall growth rate in Q2 2026; Source: Q2 2026 transcript; Trend: Lower sales
Product Brands: QIAsymphony Connect
QIAsprint Connect
QIAmini
Parse
QIAcuity
QuantiFERON
QIAstat-Dx
Qiagen Digital Insights
QDI
Evercode
Franklin

Bull / Bear Details

Qiagen (QGEN) maintains a bullish outlook as a vital provider of high-margin sample-to-insight solutions, driven by strong performance in its growth pillars lik

Thesis

Qiagen (QGEN) maintains a bullish outlook as a vital provider of high-margin sample-to-insight solutions, driven by strong performance in its growth pillars like Sample Technologies, QIAcuity digital PCR, and Qiagen Digital Insights. New product launches and automation initiatives are accelerating market penetration and offsetting headwinds from specific segments and a cautious funding environment, positioning the company for stronger second-half 2026 growth and continued profitability. (Updated: 2026-08-14)

Bull case

QGEN's accelerating product innovation and automation strategy, including new Sample Technologies instruments (QIAsymphony Connect, QIAsprint Connect, QIAmini), QIAcuity digital PCR expansion, and QIAstat-Dx menu additions (BCID panels, complicated UTI), are driving market share gains and expanding its addressable market. The outperformance of Parse in single-cell analysis further underscores successful portfolio diversification and technological leadership.
The consistent above-market growth of QGEN's key pillars—Sample Technologies, QIAcuity, and Qiagen Digital Insights—demonstrates strong underlying demand for its high-margin solutions. The company's ability to maintain high profitability (29.4% adjusted operating income margin) and generate robust cash flow provides financial flexibility for continued investment and shareholder returns, including a 40% dividend increase.
QGEN is strategically expanding into high-growth areas, leveraging AI for drug discovery through its QDI collaboration with NVIDIA and developing AI-enabled tools for TB risk assessment. The planned fully automated QuantiFERON workflow and unique QIAstat complicated UTI panel address significant unmet clinical needs, enhancing competitive differentiation and long-term growth prospects.

Bear case

QGEN faces challenges from segment-specific headwinds, such as the significant decline in U.S. immigration testing demand impacting QuantiFERON sales and weaker OEM demand affecting PCR and nucleic acid amplification. QIAstat-Dx's performance is also susceptible to challenging prior-year comparisons in respiratory testing and regional market declines in key areas like China, Germany, France, and Italy.
Despite sequential improvements, the U.S. life science funding environment remains cautious, with NIH outlay in H1 2026 still below H1 2025 levels. This can impact capital sales and laboratories' ability to invest in new instruments, potentially slowing the uptake of QGEN's new automation systems and affecting overall instrument revenue growth.
The diagnostics and early detection space is highly competitive, with new entrants in latent TB testing and existing competition. While QGEN is prepared to compete, intensifying competition could lead to pricing pressures. Additionally, lengthy regulatory approval processes, such as for QIAstat BCID panels in the U.S. and the future complicated UTI panel, pose potential delays to market expansion.

Bull / Bear Case

Bear Case: The bear case for Qiagen centers on persistent segment-specific headwinds and a cautious market environment. QuantiFERON sales continue to be impacted by a significant decline in U.S. immigration testing demand, and QIAstat-Dx faces challenging prior-year comparisons in respiratory testing. Weaker OEM demand also affects PCR and nucleic acid amplification. Despite sequential improvements, the U.S. life science funding environment remains constrained, with NIH outlay in H1 2026 still below H1 2025 levels, potentially slowing capital sales and new instrument adoption. Regional market declines in key areas like China and parts of Europe also present challenges. Additionally, intensifying competition in latent TB testing and lengthy regulatory approval processes for new diagnostics pose ongoing risks to market expansion and pricing power.
Bull Case: Qiagen's bull case is anchored by its strong Q2 2026 performance, exceeding sales and adjusted EPS outlook, and a reaffirmed full-year guidance anticipating stronger growth in the second half. This acceleration is driven by robust contributions from key growth pillars like Sample Technologies, QIAcuity digital PCR, and Qiagen Digital Insights, which consistently deliver above-market growth. The company's aggressive automation strategy and new product launches, including QIAsymphony Connect, QIAsprint Connect, QIAmini, and the recently FDA-cleared QIAstat-Dx BCID panels, are expanding its addressable market and driving market share gains. Furthermore, the outperformance of Parse in single-cell analysis and strategic collaborations in AI for drug discovery highlight successful diversification and technological leadership. High profitability and strong cash flow provide financial flexibility for continued innovation and shareholder returns.
More Compelling & Why: Bull Case. Qiagen's current P/E ratio of approximately 21.7x is notably below the life sciences industry average of 37.6x, suggesting the market has not fully priced in its growth potential. The strongest argument is the reaffirmed full-year outlook, with management confidently projecting a significant sales acceleration in H2 2026, driven by new product launches and easing comparisons. This, combined with strong profitability and recent FDA clearances, makes the bull case more compelling. My view would flip if the anticipated H2 acceleration fails to materialize or if U.S. life science funding deteriorates further.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
QIAstat-Dx BCID Panel FDA Approval for U.S.	FDA approval will unlock the U.S. market for QIAstat's new bloodstream infection panels, addressing a significant clinical need and diversifying QIAstat's revenue beyond respiratory testing, driving growth in a key segment.	Official announcement of FDA 510(k) clearance or PMA approval for QIAstat-Dx BCID panels by the end of 2026.	FDA approval by end of 2026 = bullish signal for QIAstat-Dx growth and market expansion. Delay or rejection = bearish signal.	Company press releases, FDA 510(k) clearances database, Q3/Q4 2026 earnings calls.	FDA 510(k) database search for 'Qiagen QIAstat-Dx BCID'. Industry news sites (e.g., GenomeWeb, Fierce Biotech) for regulatory updates.
Parse Single-Cell Analysis Sales Outperformance	Parse is a relatively new acquisition that is already exceeding expectations. Continued outperformance indicates successful integration, strong market demand for its differentiated single-cell solutions, and a significant growth driver for Sample Technologies.	Management commentary on Parse's sales contribution and growth trajectory in Q3/Q4 2026 earnings, specifically if it continues to exceed the original $40 million target for 2026.	Continued commentary on Parse exceeding its $40M sales target for 2026 = bullish. Any slowdown in growth or failure to exceed the target = bearish.	Q3/Q4 2026 earnings calls and reports.	Google Trends: 'Parse single cell analysis' or 'Parse Biosciences' search volume. Academic publications citing Parse technology.	Thinknum: Job postings for 'Parse Biosciences' or 'single-cell analysis sales' at Qiagen.
QuantiFERON Sales Performance vs. $500M Target	QuantiFERON is a significant revenue contributor. Achieving the $500 million target for 2026, despite reduced U.S. immigration testing, demonstrates the resilience and growth in other applications and market share gains.	QuantiFERON sales growth in Q3 and Q4 2026, and management's commentary on progress towards the $500 million full-year target.	QuantiFERON sales growth in H2 2026 that keeps the company on track for the $500M target = bullish. Significant underperformance in Q3, especially given the strong Q3 2025 comp, leading to a revised target = bearish.	Q3/Q4 2026 earnings calls and reports.	Google Trends: 'QuantiFERON test' search volume, particularly in non-U.S. regions or for specific applications like 'diabetes TB testing'.	Earnest Analytics: Diagnostic test volume data for QuantiFERON.
U.S. Life Science Funding Trends (NIH Outlay & Capital Sales)	Funding for research and academia, particularly NIH outlay, directly influences capital equipment purchases (instruments) by labs, impacting Qiagen's overall sales, especially for new instrument launches.	NIH funding updates (e.g., quarterly reports), management commentary on capital sales trends and funding environment in Q3/Q4 2026 earnings.	Sustained sequential improvement in NIH outlay and positive commentary on capital sales = bullish. Continued year-over-year decline in NIH outlay or worsening capital sales trends = bearish.	NIH website for funding data (e.g., grants.nih.gov), Q3/Q4 2026 earnings calls.	NIH Reporter database for new grant awards in genomics/molecular diagnostics.	Earnest Analytics: Capital equipment sales trends in life sciences.
New Sample Technologies Instrument Placements & QIAmini Launch	Successful placements of QIAsymphony Connect and QIAsprint Connect, along with the QIAmini launch, are critical for driving future consumables revenue and expanding Qiagen's automation footprint, a key growth pillar.	Number of QIAsymphony Connect and QIAsprint Connect placements disclosed in Q3/Q4 2026 earnings, and the successful commercial launch of QIAmini in Fall 2026.	High number of placements (e.g., exceeding internal targets) and on-time QIAmini launch = bullish. Slower than expected placements or QIAmini delays = bearish.	Q3/Q4 2026 earnings calls and reports, company press releases for QIAmini launch.	Company job postings for field service engineers or sales specialists for 'QIAsymphony Connect', 'QIAsprint Connect', 'QIAmini' (e.g., LinkedIn, company careers page).	Thinknum: Sales/Field Service Engineer job postings growth for 'Qiagen Sample Technologies' or specific instrument names.

Key Reported Metrics, Reratings Triggers & Results3 rows

After facing headwinds from reduced U.S. immigration testing, QuantiFERON returned to growth in Q2. Its performance against the $500 million full-year target an

Upcoming print · 2026-11-03

Key reported metrics
Metric	Last period	Why it matters
QuantiFERON Sales Growth at CER	1%	After facing headwinds from reduced U.S. immigration testing, QuantiFERON returned to growth in Q2. Its performance against the $500 million full-year target and the impact of new applications and automated workflows will be critical for investor confidence in this significant product line.
Sample Technologies Sales Growth at CER	9%	Sample Technologies is a key growth pillar, consistently delivering above-market growth. Its continued strong performance, driven by automation strategy and new instrument launches like QIAsymphony Connect and QIAsprint Connect, is crucial for future revenue expansion and market share gains.
Total Net Sales Growth at CER	0%	This is the primary indicator of Qiagen's overall top-line performance. Investors will closely watch this metric to assess the company's ability to achieve its reaffirmed full-year outlook and the expected acceleration in the second half of 2026, driven by new product launches and easing headwinds.

Key Questions

Will the new product launches and easing headwinds be sufficient to drive the projected sales acceleration in Q3 2026, especially given the strong prior-year co

Will the new product launches and easing headwinds be sufficient to drive the projected sales acceleration in Q3 2026, especially given the strong prior-year comparable for QuantiFERON?

Question 2: Will QuantiFERON's growth in other applications and the launch of new QIAstat-Dx panels offset the impact of reduced immigration testing and challenging prior-year comparisons to drive overall Diagnostic Solutions growth in Q3 2026?
Question 3: To what extent will improving U.S. life science funding and the successful uptake of new Sample Technologies instruments, including Parse's continued outperformance, mitigate broader market caution and contribute to capital sales growth in Q3 2026?

Earnings Transcript SummaryTable

2026-08-05 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Delivering on Outlook and Profitable Growth: Management emphasized exceeding Q2 2026 sales and adjusted EPS outlook, while maintaining a high level of profitability and continuing to invest in their portfolio for future growth. They reaffirmed the full-year outlook and expressed confidence in stronger growth in the second half of 2026. 2. Performance of Growth Pillars and New Launches: Focus was placed on the continued strong performance of key growth areas like Sample Technologies, QIAcuity, and Qiagen Digital Insights, with QuantiFERON returning to growth. Management also highlighted significant progress with new product launches, including QIAsymphony Connect, QIAsprint Connect, QIAmini, and new QIAstat BCID panels, which are expected to drive second-half growth. 3. Strategic Review and Shareholder Value: Thierry Bernard reiterated that the company is continuously assessing options to increase shareholder and stakeholder value, viewing the strategic review as an ongoing process complementary to the CEO search.	Call Takeaway & ToneThe overall takeaway of the call was one of cautious optimism. Management delivered Q2 2026 results above their outlook for both sales and adjusted EPS, demonstrating business resilience. They maintained a high level of profitability and highlighted strong performance from their growth pillars and progress in new product launches. The tone was confident regarding the reaffirmed full-year outlook and expected stronger growth in the second half of 2026, driven by new product contributions and easing comparisons. However, management also expressed caution regarding U.S. life science funding and the impact of reduced immigration testing demand on QuantiFERON, which led to a revised full-year outlook earlier in the year. The ongoing strategic review and CEO search were presented as continuous efforts to enhance shareholder value.	Prior Quarter'S Y/Y Growth By SegmentSample Technologies: 9% CER growth. Diagnostic Solutions: 4% CER decline. QuantiFERON: 5% CER decline. QIAstat-Dx: 1% CER decline. PCR and nucleic acid amplification: 13% CER decline. QIAcuity: double-digit CER sales growth. Genomics and NGS product group: 4% CER growth. Qiagen Digital Insights (QDI): solid single-digit gains.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Updated Full-Year Guidance and Back-Half Acceleration: Analysts questioned the updated guidance for the back half of the year and the drivers behind the expected acceleration. Management responded by citing the end of headwinds from discontinued products (NeuMoDx and DIALUNOX), increasing contributions from new Sample Tech systems and other product launches (QIAsymphony Connect, QIAsprint Connect, QIAstat BCID panels, QIAcuity offerings), and the outperformance of Parse. 2. QuantiFERON Performance and Competition: Analysts inquired about the softened language on the full-year QuantiFERON target and potential competitive headwinds. Management explained that the Q1 2026 decision to reduce revenue expectations by $35 million due to decreased U.S. immigration testing demand was appropriate. They noted QuantiFERON's return to positive growth in Q2 2026 and highlighted progress in other applications (e.g., diabetes, dialysis patients) and new developments like the fully automated workflow with Inpeco and an AI-enabled tool for TB risk assessment. Management also stated that new competitors could increase overall market awareness for latent TB testing and that they are prepared to compete. 3. Strategic Review and Capital Deployment: Analysts pressed for details on the ongoing strategic review, including whether portfolio changes, restructuring, or different capital allocation were on the table, and how it relates to the CEO search. Management clarified that the strategic review is a continuous process to assess pathways for increased shareholder value, independent but complementary to the CEO search. Regarding capital deployment, specifically the lack of share buybacks in Q2 despite authorization, management attributed it to a technical opposition period for debt holders in Europe after an AGM, which typically lasts 2-3 months.	Revenue SegmentsSample Technologies: 9% CER growth. Diagnostic solutions: 2% CER decline. QuantiFERON: 1% CER growth. QIAstat-Dx: 7% CER decline. PCR and nucleic acid amplification: 8% CER decline. QIAcuity: double-digit CER growth. Genomics and NGS product group: 2% CER growth. Qiagen Digital Insights (QDI): solid single-digit growth. Consumables for universal NGS panels: more than 20% CER growth.

Transcript TidbitsTable

2026-08-05

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketQiagen is expanding its eligible market through several initiatives, including the commercial launch of QIAsymphony Connect and QIAsprint Connect, new IVD compliant automation systems, with QIAmini on track for launch in the fall. In single cell analysis, Parse launched next-generation immune profiling solutions and was selected for a NASA-supported research program. For latent tuberculosis testing, Qiagen plans to launch the first fully automated Sample to Insight workflow in the second half of 2027, combining sample handling, incubation, and detection, and is developing an AI-enabled tool to assess the risk of progression to active TB. The QIAstat menu is expanding into bloodstream infection testing in Europe with two new BCID panels, which are expected to receive FDA approval for the U.S. by the end of the year. The large gastrointestinal panel is also helping laboratories respond to increasing demand during the ongoing cyclospora outbreak in the U.S. In digital PCR, the QIAcuity portfolio is expanding with new gene expression assays and a high multiplex kit for up to 12 RNA targets, along with broader workflow automation through a collaboration with Hamilton. Qiagen Digital Insights (QDI) is collaborating with NVIDIA to combine curated biomedical knowledge with accelerated computing and graph-based AI to accelerate drug discovery. The company is also developing a complicated UTI panel for QIAstat, expected to be available in Europe in the second half of 2027, addressing a significant unmet clinical need.	About CompetitionQiagen acknowledges the presence of new competitors entering the latent TB testing market, which it views positively as it may increase awareness and the total available market for latent TB testing worldwide. The company states that its main competitor for QuantiFERON remains the traditional skin test (TST), and it has had existing competition for many years with Revvity. Qiagen does not currently see an impact on its market shares from new entrants and is prepared to compete commercially and product-wise. For its Parse single cell analysis solution, Qiagen highlights its differentiation, noting it is an instrument-free solution with uncomparable ease of use and the ability to cover a large number of cells. Regarding the complicated UTI panel for QIAstat, Qiagen believes none of its competitors currently have or have announced development of such a panel, giving it a unique position.	About The Broader IndustryThe broader industry is experiencing sequential improvement in funding for research and academia, particularly in the U.S., although NIH outlay in H1 2026 is still lower compared to H1 2025. This lack of funding can sometimes impact capital sales and laboratories' ability to invest in new instruments. AI is becoming increasingly important in biomedical research as researchers work with growing amounts of data. There is a trend of more customers moving from qPCR to digital PCR. The latent tuberculosis screening market continues to expand, and bloodstream infections are a key issue requiring rapid treatment decisions. Syndromic testing for respiratory panels accounts for roughly 65% of total testing volume, and the industry has seen weaker flu seasons over the last 12 months. While some life science companies have highlighted improving order trends in lab instruments in Q2, Qiagen's capital sales performance reflects lower overall funding and the progressive uptake of new launches.	Where Things Are HeadedQiagen is reaffirming its full-year 2026 outlook and remains confident in stronger growth during the second half of the year, expecting CER sales growth to improve from minus 1% in the first half to about 3% to 4% in the second half. Growth is expected to be weighted towards the fourth quarter, benefiting from incremental contributions from new product launches and an easier prior-year comparison due to the U.S. government shutdown in Q4 2025. QuantiFERON is tracking towards its $500 million target for 2026, with growth expected to strengthen in 2027 with the launch of the fully automated Sample to Insight workflow and an AI-enabled tool for TB progression risk. QIAstat is anticipated to achieve double-digit growth in the second half of the year, supported by new panels and the upcoming winter flu season. The company expects to launch the QIAmini instrument in the fall and secure FDA approval for its BCID panels by the end of the year. New gene expression assays and a high multiplex kit for QIAcuity are planned for launch in the second half of the year. A complicated UTI panel for QIAstat is targeted for availability in Europe in the second half of 2027. Qiagen emphasizes that continuously assessing pathways to improve shareholder value is an ongoing process for management and the Board.	Updates On ThemeDiagnostics	Broader Themes EmergingAI is emerging as a broader theme, being increasingly important in biomedical research for turning complex biological data into meaningful insights and accelerating drug discovery through collaborations combining curated biomedical knowledge with accelerated computing and graph-based AI. AI is also being applied to develop tools for assessing the risk of progression to active TB.	Bullish-Leaning Quotes (Short)We exceeded our outlook for both sales and adjusted EPS. Our growth pillars delivered 5% growth at CER, profitably above market growth. We maintain a very high level of profitability. We are reaffirming our full year outlook and remain confident in stronger growth during the second half of the year. Parse, which is performing ahead of our original '26 sales target of about USD 40 million. The potential of that test [complicated UTI], given the unmet need that I highlighted at the beginning is significant.	Bearish-Leaning Quotes (Short)This U.S. immigration testing demand decrease is what we highlighted at the end of our Q1 2026. QIAstat Diagnostic was impacted by a challenging prior year comparison in respiratory testing. This was more than offset by weaker OEM demand. While Spain, Belgium and Poland were up in the quarter, Germany, France and Italy were down. China was down in the low teens. If you consider, for example, the funding coming from NIH in the U.S., it is still below in H1 of 2026 compared to H1 2025. The lack of funding sometimes reflects on capital sales and abilities from labs to invest into new instruments. Q3, we are going to be slightly impacted by a very strong comp of Q3 2025, especially in the U.S.	HiringIn the U.S., which remains the main market for syndromic testing, we have taken significant decisions from an organization standpoint, new sales, salespeople on the field, more specialized, new leadership.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-05	Qiagen exceeded Q2 2026 sales and EPS, reaffirming its full-year outlook with confidence in stronger H2 growth driven by new product launches and growth pillars. Despite cautious funding and QuantiFERON headwinds, profitability remained high. The stock outperformed SPY post-earnings, indicating positive market reception to the beat and reaffirmed guidance.	Earnings Transcript	Neutral		+0.83% (vs SPY: +0.41%)

Upcoming Events2 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
QGEN_d36fa6f0	this fall	2026-09-01	2026-11-30	Commercial launch of QIAmini, a new instrument in the Sample Technologies portfolio.	As a new instrument launch, QIAmini is expected to contribute to the company's growth in the second half of 2026 and generate future consumables revenue, reinforcing the automation strategy.	Ticker	2026-08-05	earnings_transcript
QGEN_61c17649	by the end of the year	2026-10-01	2026-12-31	FDA approval for QIAstat BCID (Bloodstream Infection Detection) panels in the U.S.	This approval will enable the expansion of the QIAstat-Dx menu into the critical U.S. bloodstream infection testing market, driving future revenue growth and strengthening the platform's competitive position.	Ticker	2026-08-05	earnings_transcript